Celastrol blocks interleukin-6 gene expression via downregulation of NF-κB in prostate carcinoma cells

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Chiang, Kun Chun ^a   Tsui, Ke Hung ^a   Chung, Li Chuan ^b   Yeh, Chun Nan ^a   Chen, Wen Tsung ^c   Chang, Phei Lang ^a   Juang, Horng Heng ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c NATIONAL KAOHSIUNG UNIVERSITY OF HOSPITALITY AND TOURISM   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CELASTROL; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN P50; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; IL6 PROTEIN, HUMAN; TRIPTERINE; TRITERPENE; TUMOR PROTEIN;

5' UNTRANSLATED REGION; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSIVE ELEMENT; DOWN REGULATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELETION; GENE EXPRESSION; GENE MUTATION; NONHUMAN; PROSTATE CARCINOMA; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; BIOSYNTHESIS; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MALE; NEOPLASM PROTEINS; NF-KAPPA B; PROSTATIC NEOPLASMS; TRITERPENES;

EID: 84899745281     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093151     Document Type: Article

References (38)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28: 555-565. (Pubitemid 32916759)
3. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D (2002) Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20: 4567-4573. (Pubitemid 35402960)
4. Gullett NP, Ruhul Amin AR, Bayraktar S, Pezzuto JM, Shin DM, et al. (2010) Cancer prevention with natural compounds. Semin Oncol 37: 258-281.
5. Salminen A, Lehtonen M, Paimela T, Kaarniranta K (2010) Celastrol: Molecular targets of Thunder God Vine. Biochem Biophys Res Commun 394: 439-442.
6. Zhu H, Liu XW, Ding WJ, Xu DQ, Zhao YC, et al. (2010) Up-regulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L. Cancer Lett 297: 155-164.
7. Sung B, Park B, Yadav VR, Aggarwal BB (2010) Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors. J Biol Chem 285: 11498-11507.
8. Yang H, Chen D, Cui QC, Yuan X, Dou QP (2006) Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66: 4758-4765.
9. He D, Xu Q, Yan M, Zhang P, Zhou X, et al. (2009) The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer 9: 343.
10. Guo Y, Xu F, Lu T, Duan Z, Zhang Z (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38: 904-910.
11. Edwards J, Bartlett JM (2005) The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. BJU Int 95: 1327-1335. (Pubitemid 40799455)
12. Jia L, Choong CS, Ricciardelli C, Kim J, Tilley WD, et al. (2004) Androgen receptor signaling: mechanism of interleukin-6 inhibition. Cancer Res 64: 2619-2626. (Pubitemid 38523920)
13. Xiao W, Hodge DR, Wang L, Yang X, Zhang X, et al. (2004) Co-operative functions between nuclear factors NFkappaB and CCAT/enhancer-binding protein-beta (C/EBP-beta) regulate the IL-6 promoter in autocrine human prostate cancer cells. Prostate 61: 354-370. (Pubitemid 39564278)
14. Pang X, Yi Z, Zhang J, Lu B, Sung B, et al. (2010) Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res 70: 1951-1959.
15. Dai Y, DeSano JT, Meng Y, Ji Q, Ljungman M, et al. (2009) Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer. Int J Radiat Oncol Biol Phys 74: 1217-1225.
16. Juang HH, Chung LC, Sung HC, Feng TH, Lee YH, et al. (2013) Metallothionein 3: An androgen-upregulated gene enhances cell invasion and tumorigenesis of prostate carcinoma cells. Prostate 73: 1495-1506.
17. Chung LC, Tsui KH, Feng TH, Lee SL, Chang PL, et al. (2012) L-Mimosine blocks cell proliferation via upregulation of B-cell translocation gene 2 and N-myc downstream regulated gene 1 in prostate carcinoma cells. Am J Physiol Cell Physiol 302: C676-685.
18. Tsui KH, Chang YL, Feng TH, Chung LC, Lee TY, et al. (2012) Growth differentiation factor-15 upregulates interleukin-6 to promote tumorigenesis of prostate carcinoma PC-3 cells. J Mol Endocrinol 49: 153-163.
19. Tsui KH, Wang SW, Chung LC, Feng TH, Lee TY, et al. (2013) Mechanisms by which interleukin-6 attenuates cell invasion and tumorigenesis in human bladder carcinoma cells. Biomed Res Int 2013: 791212.
20. Tsui KH, Feng TH, Chung LC, Chao CH, Chang PL, et al. (2008) Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line. Anticancer Res 28: 1969-1976.
21. Tsui KH, Feng TH, Hsieh WC, Chang PL, Juang HH (2008) Expression of interleukin-6 is downregulated by 17-(allylamino)-17-demethoxygeldanamycin in human prostatic carcinoma cells. Acta Pharmacol Sin 29: 1334-1341.
22. Kannaiyan R, Shanmugam MK, Sethi G (2011) Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett 303: 9-20.
23. Imada K, Leonard WJ (2000) The Jak-STAT pathway. Mol Immunol 37: 1-11. (Pubitemid 30316189)
24. Ara T, Declerck YA (2010) Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 46: 1223-1231.
25. Jee SH, Chu CY, Chiu HC, Huang YL, Tsai WL, et al. (2004) Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. J Invest Dermatol 123: 1169-1175.
26. Bellone S, Watts K, Cane S, Palmieri M, Cannon MJ, et al. (2005) High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy- resistant variant of endometrial cancer. Gynecol Oncol 98: 92-98. (Pubitemid 40826424)
27. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, et al. (2001) Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 61: 8851-8858. (Pubitemid 34013900)
28. Cozen W, Gill PS, Ingles SA, Masood R, Martinez-Maza O, et al. (2004) IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood 103: 3216-3221. (Pubitemid 38451701)
29. Cardillo MR, Ippoliti F (2006) IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Anticancer Res 26: 3409-3416. (Pubitemid 44701516)
30. Steiner H, Cavarretta IT, Moser PL, Berger AP, Bektic J, et al. (2006) Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328. Prostate 66: 1744-1752. (Pubitemid 44893900)
31. George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, et al. (2005) The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 11: 1815-1820. (Pubitemid 40471844)
32. Basseres DS, Baldwin AS (2006) Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25: 6817-6830. (Pubitemid 44657854)
33. Napetschnig J, Wu H (2013) Molecular basis of NF-kappaB signaling. Annu Rev Biophys 42: 443-468.
34. Baud V, Karin M (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8: 33-40.
35. Pomerantz JL, Baltimore D (2002) Two pathways to NF-kappaB. Mol Cell 10: 693-695.
36. Keller ET, Chang C, Ershler WB (1996) Inhibition of NFkappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone- mediated repression of the interleukin-6 promoter. J Biol Chem 271: 26267-26275. (Pubitemid 26347476)
37. Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, et al. (2006) Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol 72: 1311-1321. (Pubitemid 44572192)
38. Malinin NL, Boldin MP, Kovalenko AV, Wallach D (1997) MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 385: 540-544. (Pubitemid 27074673)